翻訳と辞書 |
ANA773
ANA773 is an experimental oral prodrug of isatoribine developed by Anadys Pharmaceuticals which forms an active metabolite that is an agonist for TLR7. It causes an induction of endogenous type 1 interferons. It is designed to treat hepatitis C. Early clinical trials found it to be well tolerated and to have potent antiviral activity irrespective of viral genotype, viral load, gender or previous response to IFN based therapies. ==Development== Phase I trials ended in 2009 and showed ANA773 to have potent antiviral activity at a well tolerated dose. As such, Anadys's CEO described it as "a potential replacement for injectable interferon."〔http://www..com/clinical_trials/ana773-demonstrates-significant-antiviral-response-early-clinical-trial--c--7906.html〕 In late 2011, Anadys was acquired by Roche, which planned to continue development of this drug.〔http://www.roche.com/media/media_releases/med-cor-2011-10-17.htm〕
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「ANA773」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|